GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Net Policyholder Benefits/Claims

Tvardi Therapeutics (LTS:0HTC) Net Policyholder Benefits/Claims


View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Net Policyholder Benefits/Claims?

Net Policyholder Benefits/Claims only applies to insurance companies.


Tvardi Therapeutics Business Description

Traded in Other Exchanges
Address
3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Website
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.